- Home
- JSPR vs RZLT Comparison
JSPR vs RZLT Comparison
Compare JSPR & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- RZLT
- Stock Information
- Founded
- JSPR 2018
- RZLT 2010
- Country
- JSPR United States
- RZLT United States
- Employees
- JSPR N/A
- RZLT N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- RZLT Health Care
- Exchange
- JSPR Nasdaq
- RZLT Nasdaq
- Market Cap
- JSPR 85.8M
- RZLT 361.3M
- IPO Year
- JSPR N/A
- RZLT N/A
- Fundamental
- Price
- JSPR $3.31
- RZLT $5.11
- Analyst Decision
- JSPR Buy
- RZLT Strong Buy
- Analyst Count
- JSPR 12
- RZLT 6
- Target Price
- JSPR $31.67
- RZLT $12.00
- AVG Volume (30 Days)
- JSPR 1.4M
- RZLT 1.5M
- Earning Date
- JSPR 08-12-2025
- RZLT 05-13-2025
- Dividend Yield
- JSPR N/A
- RZLT N/A
- EPS Growth
- JSPR N/A
- RZLT N/A
- EPS
- JSPR N/A
- RZLT N/A
- Revenue
- JSPR N/A
- RZLT N/A
- Revenue This Year
- JSPR N/A
- RZLT $35.39
- Revenue Next Year
- JSPR N/A
- RZLT N/A
- P/E Ratio
- JSPR N/A
- RZLT N/A
- Revenue Growth
- JSPR N/A
- RZLT N/A
- 52 Week Low
- JSPR $2.27
- RZLT $2.22
- 52 Week High
- JSPR $26.05
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- JSPR 34.76
- RZLT 65.73
- Support Level
- JSPR $2.71
- RZLT $4.15
- Resistance Level
- JSPR $4.00
- RZLT $5.44
- Average True Range (ATR)
- JSPR 0.60
- RZLT 0.30
- MACD
- JSPR -0.25
- RZLT 0.05
- Stochastic Oscillator
- JSPR 21.22
- RZLT 75.00
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.